By Neuroscience News
A novel vaccine, targeting inflamed brain cells, could potentially prevent or alter the course of Alzheimer's disease.
The vaccine takes aim at senescence-associated glycoprotein (SAGP), linked to the debilitating illness.
Tested in mice, the vaccine revealed its potency by reducing amyloid deposits and decreasing inflammatory biomarkers.
These amyloid deposits and inflammatory markers are key contributors to Alzheimer's disease progression.
Mice treated with the vaccine exhibited increased awareness of their surroundings.
This improved awareness suggests the potential for lessening the symptoms of Alzheimer's disease in humans.
Preliminary research shines a light on a promising path towards effective treatment for this widespread disease.
This groundbreaking Alzheimer's vaccine offers renewed hope to millions worldwide affected by the disease.